[The efficacy and safety of autologous cryopreserved platelet transfusion in management of thrombocytopenia after chemotherapy in hematological malignancy].
To investigate the efficacy and safety of autologous cryopreserved platelet transfusion in the management of thrombocytopenia after chemotherapy in hematological malignancy. A total of 40 patients diagnosed as hematological malignancy with complete remission were equally assigned into study group and control group. During chemotherapy interval in the study group, when platelet counts exceeded 120 × 10(9)/L, autologous platelets were collected with CS3000 Cell Separator and cryopreserved at -80°C with 5% dimethylsulfoxide. When platelet counts dropped below 15 × 10(9)/L after chemotherapy, autologous platelets were thawed with 40°C water bath and transfused back to each patient. In the control group, when platelet counts dropped below 15 × 10(9)/L after chemotherapy, allogeneic fresh platelets were transfused. Median loss during the freeze-thaw-wash procedure in study group was observed, and the 1 h, 24 h corrected count increments (CCI) were calculated in the both groups. The hemostatic effects and adverse reactions were also observed. In the control group, 1hCCI and 24h CCI were (19.3 ± 6.1) × 10(9)/L and (12.2 ± 7.0) × 10(9)/L, respectively, with the effective rate of 80% and the transfusion reaction rate of 45%. Totally 20 collection and transfusions were finished in the study group. A total of (3.4 - 8.5) × 10(11) platelet were obtained in each collection. Platelet recovery after freezing and thawing was (73.51 ± 9.03)% (62% - 83%). 1hCCI was (17.4 ± 7.6) × 10(9)/L, 24h CCI was (10.5 ± 5.8) × 10(9)/L and the effective rate was 85%. There was no significant different between the two groups (P > 0.05). The transfusion reaction rate was 15%, which was significantly lower than that of the control group (P < 0.05). Meanwhile, adverse reactions were occurred less in the study group. This study demonstrates that autologous cryopreserved platelet transfusions can be safely administered for supporting thrombocytopenia in hematological malignancy patients undergoing chemotherapy.